Pay in 4 interest-free payments of $6.57 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
The Injection (Subcutaneous) - Dosing: Once weekly - Bioavailability: ~100% (bypasses GI tract) - Weight loss in trials: Up to 22% at 36 weeks - Best for: Patients seeking maximum efficacy, comfortable with self-injection The Pill (Oral) - Dosing: Once daily (taken on an empty stomach, similar to Rybelsus) - Bioavailability: Lower than SC (relies on SNAC absorption technology) - Weight loss in trials: Up to 13.1% at 12 weeks (Phase 1 short duration) - Best for: Injection-averse patients, early treatment, maintenance, broader access The oral formulation will almost certainly deliver less weight loss than the subcutaneous version at equivalent treatment durations
It is used exclusively for laboratory research and is Studies show that Cagrilintide activates amylin pathways that regulate satiety signals
Results from these trials are expected by late 2026
Research Note: Published preclinical research, including a 2025 literature and patent review in the journal Pharmaceuticals (Jzwiak et al., 2025, Pharmaceuticals ), has documented BPC-157's effects on angiogenesis, nitric oxide signaling, and tissue protection in animal models, though authors note that no completed human clinical trials have been published to confirm these effects in people
.jpg)